Home › Trial NCT05028556
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
- Trial IDNCT05028556
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorWuhan YZY Biopharma Co., Ltd.
- Enrollment50
- Start date2021-08-06
- ConditionsMetastatic or Locally Advanced Solid Tumors
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.